The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
复制标题
DOI：
10.18632/oncotarget.14698
复制
发表时间：
2017-02-28
期刊：
影响因子：
--
通讯作者：
Nakamura M
中科院分区：
文献类型：
--
作者：
Mori H;Kubo M;Yamaguchi R;Nishimura R;Osako T;Arima N;Okumura Y;Okido M;Yamada M;Kai M;Kishimoto J;Oda Y;Nakamura M
该研究纳入了2004年1月至2014年12月期间接受未新辅助化疗切除的原发性三阴性乳腺癌（TNBC）患者。在研究的248例tnbc中，103例（41.5%）肿瘤中检测到程序性细胞死亡配体-1 （PD-L1）表达，118例（47.6%）肿瘤中存在高水平的肿瘤浸润淋巴细胞（TILs）。PD-L1表达与高水平的TILs相关，但不是预后因素。高tils肿瘤患者的总生存率高于低tils肿瘤患者（P = 0.016）。PD-L1表达与TILs之间有很强的相互作用，与无复发生存（P = 0.0018）和总生存（P = 0.015）相关。多因素Cox比例风险模型分析显示，pd - l1阳性/ tils低是影响无复发生存期和总生存期的独立负预后因素。我们的研究结果提示，PD-L1阳性/TILs低的肿瘤与TNBC患者预后不良相关，肿瘤细胞上PD-L1的表达与肿瘤微环境中TILs的结合具有重要意义。这些生物标志物可能有助于tnbc的分层，预测预后和开发新的癌症免疫疗法。
This study included patients with primary triple-negative breast cancer (TNBC) who underwent resection without neoadjuvant chemotherapy between January 2004 and December 2014. Among the 248 TNBCs studied, programmed cell death ligand-1 (PD-L1) expression was detected in 103 (41.5%) tumors, and high levels of tumor-infiltrating lymphocytes (TILs) were present in 118 (47.6%) tumors. PD-L1 expression correlated with high levels of TILs, but was not a prognostic factor. Patients with TILs-high tumors had better overall survival than those with TILs-low tumors (P = 0.016). There was a strong interaction between PD-L1 expression and TILs that was associated with both recurrence-free survival (P = 0.0018) and overall survival (P = 0.015). Multivariate Cox proportional hazards model analysis showed that PD-L1-positive/TILs-low was an independent negative prognostic factor for both recurrence-free survival and overall survival. Our findings suggest that PD-L1-positive/TILs-low tumors are associated with a poor prognosis in patients with TNBC, and that it is important to focus on the combination of PD-L1 expression on tumor cells and TILs present in the tumor microenvironment. These biomarkers may be useful for stratification of TNBCs and for predicting prognosis and developing novel cancer immunotherapies.